Literature DB >> 18971550

Haplotype-based case-control study of the human CYP4F2 gene and essential hypertension in Japanese subjects.

Zhenyan Fu1, Tomohiro Nakayama, Naoyuki Sato, Yoichi Izumi, Yuji Kasamaki, Atsushi Shindo, Masakatsu Ohta, Masayoshi Soma, Noriko Aoi, Mikano Sato, Koichi Matsumoto, Yukio Ozawa, Yitong Ma.   

Abstract

CYP4F2 acts primarily as an enzyme that converts arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE), a metabolite involved in the regulation of blood pressure in humans. The aim of the present study was to assess the association between the human CYP4F2 gene and essential hypertension (EH) using a haplotype-based case-control study that included separate analysis of the two gender groups. The 249 EH patients and 238 age-matched controls were genotyped for 5 single-nucleotide polymorphisms (SNPs) of the human CYP4F2 gene (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200). Data were analyzed for 3 separate groups: all subjects, and men and women separately. For the total population and for male subjects, the distribution of the dominant model of rs1558139 (CC vs. CT+TT) differed significantly between the EH patients and control subjects (p=0.037 and p=0.005, respectively), with a higher percentage of EH patients showing the CC genotype. Logistic regression showed that, for men, the CC genotype of rs1558139 was more prevalent in the EH patients than in the control subjects (p=0.026), while, for the total population, the difference disappeared (p=0.247). For men, the overall distribution of the haplotypes was significantly different between the EH patients and the control subjects (p=0.042), and the frequency of the T-T-G haplotype was also significantly lower for EH patients than for control subjects (p=0.009). In conclusion, the present results indicate that rs1558139 might be a genetic marker for EH and the T-T-G haplotype might be a protective genetic marker for EH in Japanese men.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971550     DOI: 10.1291/hypres.31.1719

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  9 in total

1.  Urinary CYP eicosanoid excretion correlates with glomerular filtration in African-Americans with chronic kidney disease.

Authors:  Albert W Dreisbach; Stanley V Smith; Patrick B Kyle; Manjunath Ramaiah; Margaret Amenuke; Michael R Garrett; Seth T Lirette; Michael E Griswold; Richard J Roman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-08-22       Impact factor: 3.072

2.  Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.

Authors:  Kyoung-Ah Kim; Wan-Geun Song; Hae-Mi Lee; Hyun-Jin Joo; Ji-Young Park
Journal:  Mol Biol Rep       Date:  2014-07-29       Impact factor: 2.316

Review 3.  The role of 20-HETE in androgen-mediated hypertension.

Authors:  Cheng-Chia Wu; Michal Laniado Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-06-22       Impact factor: 3.072

4.  Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke.

Authors:  Anjana Munshi; Vandana Sharma; Subhash Kaul; Amal Al-Hazzani; Ali A Alshatwi; Gowhar Shafi; Rajeshwar Koppula; Sai Babu Mallemoggala; A Jyothy
Journal:  Mol Biol Rep       Date:  2011-05-31       Impact factor: 2.316

Review 5.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

Review 6.  20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension.

Authors:  Jan M Williams; Sydney Murphy; Marilyn Burke; Richard J Roman
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

Review 7.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

Review 8.  Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) rs1558139, rs2108622 polymorphisms and susceptibility to several cardiovascular and cerebrovascular diseases.

Authors:  Tao Zhang; Kuiying Yu; Xuhua Li
Journal:  BMC Cardiovasc Disord       Date:  2018-02-09       Impact factor: 2.298

9.  A Novel Polymorphism in the Promoter of the CYP4A11 Gene Is Associated with Susceptibility to Coronary Artery Disease.

Authors:  Svetlana Sirotina; Irina Ponomarenko; Alexander Kharchenko; Marina Bykanova; Anna Bocharova; Kseniya Vagaytseva; Vadim Stepanov; Mikhail Churnosov; Maria Solodilova; Alexey Polonikov
Journal:  Dis Markers       Date:  2018-02-01       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.